Gene transfer using lentiviral vectors has been recently shown to be enhanced with cis-acting elements in a cell-type-dependent manner in vivo. For this reason, the study reported here was designed to modify lentiviral vectors that express lacZ, human factor IX (FIX), or human ␣1-antitrypsin (AAT) to study the effect of different cis DNA elements on transduction efficiencies. We found that incorporation of the central polypurine tract sequence (cppt) increased transduction efficiency in vitro while increasing the transduction of non-cell-cycling hepatocytes in vivo. C57Bl/6 scid mice that were administered lentiviral vectors devoid of the cppt (2 ϫ 10 8 transducing units (T.U.)/mouse) had 81% of their lacZ-transduced hepatocytes colabeled with the cell cycle marker 5'-bromo-2'-deoxyuridine (BrdU). In contrast, inclusion of the cppt reduced the colabeling in mouse hepatocytes by 50%. Further modifications in the lentiviral vectors were performed to enhance viral titer and gene expression. We found that the inclusion of a matrix attachment region (MAR) from immunoglobulin-(Ig) significantly increased the transduction efficiency, as measured by transgene protein expression and proviral DNA copy number, compared with vectors without Ig MAR. In vitro studies using human hepatoma cells demonstrated a significant increase (two-to fourfold) in human AAT and human FIX production when the Ig MAR was incorporated. In vivo transduction of partially hepatectomized C57Bl/6 mice given an optimized lentiviral vector containing the cppt and Ig MAR (2 ϫ 10 8 T.U./mouse) resulted in sustained therapeutic levels of serum FIX (~ 65 ng/ml). Our study demonstrates the importance of cis-acting elements to enhancing the transduction ability of lentiviral vectors and the expression of vector transgenes.
INTRODUCTION
Retroviruses have been an attractive vector system for use in gene therapy, but their use has been hampered by poor in vivo transduction efficiencies [1] , in part due to the need for nuclear membrane dissolution for efficient integration to occur [2] . A variety of terminally differentiated cells in vitro and in vivo have been shown to be transduced by lentiviral vectors based on human immunodeficiency virus (HIV)-1 [3] [4] [5] . However, we found that the status of the cell cycle may have an important role in promoting efficient transduction of first-and second-generation lentiviral vectors into hepatocytes in vivo [4] . In quiescent mouse liver, 83% of the lacZpositive hepatocytes progressed through the S-phase of the cell cycle. Moreover, proliferative stimulation of liver regeneration by surgical hepatectomy or drug therapy enhanced hepatocyte transduction efficiencies by ~ 30-fold [4, 6] .
Because the replication-defective lentiviral vectors are essentially "gutted" for their native viral genes, which potentially affects their ability to infect nondividing cells in vivo and in vitro, several investigators have recently studied the role of cis-acting elements in HIV and how they affect lentiviral transduction and transgene expression [7] [8] [9] [10] . The central polypurine tract sequence (cppt), which is found within the gene pol of HIV, has been one of the more extensively studied cis-acting elements. Presence of the cppt can enhance viral titer in vitro [7] [8] [9] [10] , and significantly increase transduction of neuronal cells in vivo [9] , and human hematopoietic cells ex vivo [7] . The inclusion of the cppt has continued the debate as to whether quiescent cells in vivo, such as the hepatocytes in the liver, require cell cycling for transduction by lentiviral vectors. Pfeifer, et al. [11] , attempted to demonstrate lentiviral vec-ARTICLE doi:10.1006/mthe.2001.0450, available online at http://www.idealibrary.com on IDEAL tor transduction of noncycling hepatocytes in vivo using a modified third-generation lentiviral vector, which contained cis-acting elements that were not found in previous studies using second-generation vectors [3] [4] [5] [6] . Because there were several modifications made in the third-generation lentiviral vector, it remains to be determined whether the inclusion of the cppt alone would allow for the enhancement of lentiviral transduction in vivo.
Additional cis-acting elements are the scaffold or matrix attachment regions (MARs) [12, 13] , which have been found to increase gene expression within retroviral vectors and may have an important role in lentiviral vectors. MARs are believed to bind to the nuclear matrix of genomic DNA and establish local access of transcription factors to the enhancer/promoter sequences within the domain. Agarwal, et al. [12] , demonstrated that the MAR from the human ␤-interferon gene incorporated into a Moloney murine leukemia virus-based vector increased gene expression in primary human lymphocytes in vitro, and that long-term expression was related to the ability of the MAR to inhibit methylation of the long terminal repeats (LTR) [13] . However, there remains a plethora of MARs that have been shown to possess position-and cell-type-independent enhancing effects on transgene expression [14] [15] [16] [17] [18] , yet their mechanism of action is not fully understood.
For this reason, our study was designed to better understand the role of cis-acting elements, such as the cppt and MARs from the chicken lysozyme and immunoglobulin-gene, in terms of their effects on transduction efficiency and transgene expression within the context of lentiviral vectors in vitro and in vivo.
RESULTS

Effect of the cppt on Viral Transduction Efficiency in Vitro and in Vivo
To study the effect of the cppt on transduction efficiencies, we constructed a variety of different lentiviral vectors (Fig. 1A) and then titered them on HeLa cells in vitro. Insertion of the cppt into second-generation integrating transfer plasmids 5Ј of the expression cassette increased the transduction efficiency of the vector in HeLa cells by two-to threefold (Fig. 1B) , consistent with a previous study [7] . No significant difference was observed in the transduction efficiency when the cppt was cloned into the middle of the integrating vector (between the EF1␣ promoter and the start site of lacZ). Two copies of the cppt (Fig. 1B) resulted in a slightly higher transduction efficiency compared with the cppt-deficient vector, but it was not significantly different (P < 0.06).
As previous in vitro studies found that lentiviral vectors are not as efficient in nuclear translocation without this cis-acting cppt element, we determined the role of the cppt in liver transduction of naive C57Bl/6 mice in vivo. Lentiviral vectors (2 ϫ 10 8 transducing units (T.U.)/mouse) were administered through the portal vein into mouse liver and osmotic minipumps were inserted subcutaneously to deliver a steady-state concentration of BrdU for 7 days. Consistent with our previous study, we observed very mild liver injury at day 1 following lentiviral administration as measured by serum alanine aminotransferase (ALT; 105 ± 20 international units (I.U.)) compared with vehicle (control) mice (35 ± 5 I.U.). The serum ALT levels returned to normal levels when measured at day 3 [4, 19] . In lentiviral-treated mice with or without the cppt, the proportion of BrdU-positive hepatocytes increased about (Table 1 ). The mild liver injury, which could be attributed to factors in the viral preparation, may have caused the increased number of BrdU-positive hepatocytes compared with the control mice ( Fig. 2 and Table 1 ). The duodenum was used as a positive control for BrdU incorporation (data not shown).
In terms of the cppt and its role in mediating transduction into non-cell-cycling hepatocytes, it was found that both groups with or without the cppt had between 0.1% and 0.2% of their hepatocytes transduced (no significant difference was observed between the groups). However, mice receiving the lentiviral vector (n = 5), which contained the cppt, had a 50% lower proportion of lacZpositive cells that were colabeled with BrdU compared with mice (n = 4) given the lentiviral vector devoid of the cppt (41% versus 81%, respectively; Table 1 ). For this reason, subsequent integrating transfer plasmids used in this study included the insertion of the cppt.
Because the cppt had a role in enhancing viral transduction efficiency in vitro and reducing the need for cell cycle progression of lentiviral vectors to transduce hepatocytes in vivo, several modifications were made in the transfer vector to potentially enhance the efficiency of transduction and also reduce biosafety concerns.
Initial modifications were carried out to develop a selfinactivating (SIN) vector, whereby the 3' LTR was deleted as described [20] to remove 400 bp of the U3 region, which ultimately results in a 5' LTR deletion in the vector during reverse transcription. The woodchuck post-regulatory element (WPRE) was included in the integrating vector because previous studies showed the ability of this cis acting element to increase mRNA stability of the transgene in a retroviral construct [21] .
Also, an additional 509 bp of the envelope sequence, which contain the rev responsive element (RRE), were removed from the vector. The RRE (253 bp) was re-inserted into the 3' end of the transfer plasmid (5' to the WPRE), which effectively removed 256 bp of native HIV env sequence and potentially helped to minimize homology between wild-type HIV. The lentiviral transfer plasmids containing the cytomegalovirus (CMV) promoter driving the expression of cytoplasmic lacZ are shown schematically in Fig. 3 . The vectors were transduced into HeLa cells and gene transfer was measured by quantifying the number of lacZ-positive cells, the amount of enzyme, and/or vector DNA copy number. There was no significant difference in transduction efficiency regardless of the location of the RRE (Fig. 4A) . The presence of two RREs in the transfer vector increased the transduction efficiency by a factor of ~ 2.5 from 4.9 to 12.3 T.U./pg p24.
As we made several alterations in the lentiviral transfer vector, we wanted to demonstrate that the cppt could enhance viral transduction efficiency as in the previous second-generation vectors. As before, the cppt was cloned 5' to the expression cassette and the inclusion of this 118- bp DNA flap sequence significantly enhanced the transduction efficiency to 17.3 T.U./pg p24, which was threefold higher than the lentiviral vector without the cppt (Fig. 4B) .
To determine the role of MARs, lentiviral vectors were generated containing either the chicken lysozyme 5' MAR or the immunoglobulin-(Ig) MAR (Fig. 4B) . The individual MAR sequences were cloned 5' to the cppt (Fig. 3 ) in both sense and antisense directions. The transduction efficiency decreased to 4 T.U./pg p24 when the chicken lysozyme 5' MAR, regardless of its orientation, was inserted into the vector. However, the Ig MAR significantly increased the transduction efficiency to 37.7 and 43.8 T.U./pg p24 in the sense or antisense directions, respectively.
To quantify the transgene product, protein lysates from HeLa cells were prepared 48 hours following infection with different lentiviral preparations (Fig. 4C ). The steady-state level of ␤-galactosidase (␤-gal) protein was 77 ± 5 pg/mg protein following infection with the CMVsolLacZ lentiviral vector. Consistent with the increase in transduction efficiency, the insertion of the cppt resulted in a twofold increase in ␤-gal protein to 158 ± 2 pg/mg protein. The chicken lysozyme MAR inserted 5' into the expression cassette resulted in 108 ± 10 and 122 ± 14 pg/mg protein (in the sense and antisense orientations, respectively). For the Ig MAR, the steady state level of ␤-gal was four-to fivefold higher (836 ± 154 and 668 ± 161 pg/mg protein in the sense and antisense orientations, respectively) compared with the pHR (-)cCMVsolLacZR(+)W(+) lentiviral vector.
To ascertain whether the increased protein expression was attributable to an increased copy number of lentiviral vectors or cisacting enhancing effects by the MARs, we carried out quantitative real-time PCR analysis using isolated DNA from infected HeLa cells to demonstrate a twofold increase of lentiviral vector copies (from 0.11 ± 0.05 to 0.24 ± 0.02 copies/cell; P < 0.05) following the insertion of the cppt. Incorporation of the chicken lysozyme 5Ј MAR did not significantly alter the copies of vector genomes (Fig. 4D) , consistent with the viral transgene expression results. However, the presence of the Ig MAR, regardless of the orientation, significantly increased the number of vector genomes by ~ 2.5-fold to 0.57 ± 0.04 and 0.65 ± 0.06 from 0.24 ± 0.02 copies/cell (P < 0.001). No lentiviral DNA copies were detected in the PCR reaction using genomic DNA from un-infected HeLa cells or the control (no template) reaction. Thus, the increased ␤-gal transgene expression observed was due in part to an increase in the proviral genome copy number.
Subsequent experiments were carried out using lentiviral vectors containing similar cis DNA elements and potentially therapeutic cDNAs, specifically human factor IX (FIX; Fig. 5A ) and human ␣1-antitrypsin (AAT; Fig. 5B ). In addition to developing lentiviral vectors with liver-specific promoters, the AAT promoter including the cis-acting DNA elements from ApoE lipoprotein (A) and the hepatocyte control locus (H) [22] , was cloned into the transfer vectors to drive the expression of AAT and FIX cDNA. Different lentiviral preparations were generated and infected into Huh7 cells (a hepatoma cell line). Human FIX levels were measured by ELISA as described [19] after 24 hours. The levels of FIX (calculated as ng/10 6 cells/24 h) were significantly higher using the lentiviral vector with the cppt. The FIX levels were 47 ± 6 ng/10 6 cells/24 hours and significantly increased to 127 ± 25 ng/10 6 cells/24 hours (P < 0.001) when the cppt was inserted into the integrating construct. The insertion of the MAR from Ig regardless of the orientation significantly elevated FIX levels to 275 ± 15 (sense) and 270 ± 6 ng/10 6 cells/24 hours (antisense), respectively (P < 0.001). The 5Ј MAR from the chicken lysozyme gene was inserted into the integrating plasmid, which resulted in a statistically insignificant increase in FIX levels to 80 ± 3 (sense) and 67 ± 7 ng/10 6 cells/24 h (antisense). Expression from HeLa cells infected with the lentiviral vector containing the AAT(A/H) promoter with or without the Ig MAR did not produce any detectable FIX (data not shown), which was not unexpected because of the hepatocyte specificity of this promoter. We found that the AAT level in the medium following infection with the lentiviral vector without the cppt was 142 ± 14 ng/10 6 cells/24 hours (Fig. 5B) . Insertion of the cppt increased AAT levels approximately threefold to 415 ± 47 ng/10 6 cells/24 hours (P < 0.05). Moreover, the presence of the Ig MAR with the cppt resulted in a significant increase in steady-state levels of AAT in the medium to 1710 ± 178 ng/10 6 cells/24 hours (P < 0.005). These in vitro expression studies demonstrated the importance of cis-acting DNA elements that had a role in enhancing lentiviral titer, transgene expression, and viral DNA copy numbers.
In Vivo Transduction of Vectors Expressing FIX cDNA Using the AAT Promoter C57Bl/6 mice (8 weeks of age) were partially hepatectomized 48 hours before the administration of lentiviral vectors (50 g p24/mouse) containing the AAT(A/H)hFIX expression cassette with the cppt into the portal vein (Fig. 6 ). The pHR (-)chAAT(A/H)hFIXR(+)W(+) lentiviral vector demonstrated long-term but sub-therapeutic levels of FIX (~ 20 ng/ml; n = 3 mice) over a 10-week period. Insertion of the chicken lysozyme 5Ј MAR decreased the steady-state level of FIX bỹ 50% to ~ 10 ng/ml (n = 3 mice), which was consistent with the in vitro results. On the other hand, therapeutic levels of FIX expression were obtained from mouse serum (65 ± 10 ng/ ml; n = 3), which had the lentiviral vector with the Ig MAR administered through the portal vein. Serum FIX was undetectable (< 1.6 ng/ml) in control (vehicle) C57Bl/6 mice (n = 6) and non-hepatectomized mice, which were given similar doses of lentiviral vector (50 g p24/mouse; n = 3-6 mice/group; data not shown). 
DISCUSSION
Role of the cppt in Lentiviral Transduction in Mouse Hepatocytes in Vivo
Previous studies in our lab have found that first-and second-generation lentiviral vector transduction into mouse or rat hepatocytes in vivo was inefficient and predominantly required hepatocytes to progress into the cell cycle [4] . Investigators have found that insertion of the cppt enhances transduction of lentiviral vectors in HeLa and 293T cells in vitro. Previous studies [7] demonstrated in vivo that inclusion of the cppt resulted in a twofold elevated steady-state level of human FIX in mouse serum compared with lentiviral vectors devoid of the cppt. However, this study did not directly determine the role of the cppt in vivo within the mouse liver, specifically whether this cis element could enhance transduction into quiescent hepatocytes. Moreover, it is possible that a substantial portion of FIX gene expression comes from nonparenchymal liver, splenic cells or other non-hepatic tissue after intravascular administration of the vector [4, 11, 20] .
For this reason, the role of the cppt was investigated to determine its ability to circumvent the need for hepatocytes to enter the cell cycle for lentiviral vector transduction to occur efficiently. We found that the insertion of the cppt resulted in a 50% reduction in the requirement for cell cycling of hepatocytes in vivo. Recent studies [11] have suggested that the cell cycle was not required following intravenous administration of lentiviral vectors. Although the authors suggested that vectorological changes were a possible reason for their observed differences compared with second-generation vectors, several other possibilities exist that may have contributed to the different results between these two studies, which included the age and strain differences of the mice, but, more likely, the method by which the BrdU was administered. Pfeifer, et al. [11] , administered the BrdU into the intraperitoneal space of the mice, whereas we administered the BrdU using a subcutaneously placed osmotic minipump. It has been previously shown that intraperitoneal injections or slowreleasing pellets of BrdU substantially underestimate the number of slowly cycling cells, such as hepatocytes [23, 24] , compared with osmotic minipumps. This may explain the curious result by Pfeifer, et al. [11] , who found very few BrdU labeled hepatocytes to begin with. It is important to note that, consistent with our previous study using high doses of lentivirus [4] , Pfeifer, et al. [11] , found that this vector system can also transduce non-parenchymal liver and splenic cells.
Moreover, because no comparisons with previous versions of the vector were made, our study confirms that the cppt can, in part, alleviate the need for cell cycle progression in order for lentiviral vectors to integrate into mouse 
Effect of Cis Elements on Viral Titer and Transduction Efficiencies in Vitro
Because the cppt had a role in enhancing viral titer in vitro and minimizing the requirement for hepatocytes to enter the cell cycle to transduce lentiviral vectors in vivo, we made further modifications to the lentiviral integrating vectors to optimize the viral titer, transgene expression, and, potentially, biosafety of the vector system. Initial alterations in the second-generation transfer plasmids were made to delete 400 bp of the U3 region in the 3Ј LTR, which results in the production of a SIN vector. This was believed to help in reducing the likelihood for generating replication-competent retroviruses from producing cell lines. In addition, the integrated provirus would be unable to initiate transcription from the LTR, avoiding the possibility of activating a "dormant" gene within the cell and affecting transcription from the internal promoter within the vector. The env sequence from the HIV genome surrounding the RRE was removed and replaced with a PCRamplified RRE (253 bp) without surrounding env sequence in the 3Ј region of the transfer plasmid 5Ј to the WPRE. No significant effect on transduction efficiency was determined, which suggests that the RRE can function regardless of the position in the lentiviral transfer vector. We found that insertion of the cppt regardless of whether it is near the 5Ј end or in the center of the transfer plasmid significantly increased viral transduction efficiency (as measured by transducing units/pg p24). We found that the transduction efficiency and/or gene expression increased in the presence of the cppt in a promoterand cell-type-independent manner. The increased viral titer and transduction efficiency was consistent with previous studies examining the role of the cppt in vitro [7] [8] [9] [10] .
MARs are stretches of DNA that are thought to determine chromatin structure and may have a role in opening specific domains for transcription to potentially augment gene expression. For this reason, lentiviral constructs were developed that contained either the MAR from the 5Ј chicken lysozyme or the Ig gene. These MARs were previously found to have cis-acting enhancing effects on transgene expression in a cell-type-and position-independent manner in vitro [14] [15] [16] [17] [18] , but the mechanism by which these MARs function biologically is still unknown. Previous studies using human ␤-interferon MARs in murine Moloney-based retroviruses resulted in long-term increases in gene expression in primary T cells [12, 13] . Here, we found that the chicken lysozyme 5Ј MAR decreased the viral transduction efficiency, but did have some cis-acting enhancer effect on transgene expression. The cis-acting enhancer effect is consistent with previous in vitro and transgenic mouse studies using the chicken lysozyme 5Ј MAR.
In contrast, the inclusion of the MAR from the Ig gene significantly enhanced the transduction efficiency and transgene expression using either the CMV or the AAT promoter in the transfer vector. The cis-enhancing effect by the Ig MAR was consistent with previous studies, which found that the deletion of the MAR significantly blunted the transgene expression of the Ig gene [18] . Although the mechanism by which the Ig MAR enhanced viral transduction efficiency and gene expression was not studied, it may act through lentiviral integration by enhanced lentiviral RNA encapsidation or perhaps by binding to the DNA matrix and stabilizing the vector, allowing it more favorable access to integration sites, which may aid in facilitating transcription factors to activate the internal promoter of the lentivirus. Further investigation into the mechanism of the Ig MAR is needed.
Role of Cis-Acting Elements on In Vivo Lentiviral Transduction
Although we have previously achieved therapeutic levels of FIX in the serum of mice given lentiviral vectors using the EF1 ␣promoter, the dose of the viral vector was very high (more than 100 g p24) or lentiviral administration was performed following proliferative induction by surgical partial hepatectomy [19] .The results in the present study also demonstrated that a liver-specific promoter (human AAT) driving the expression of FIX cDNA in a potentially more biosafe lentiviral vector produced longterm therapeutic levels (> 50 ng/ml) of FIX in partially hepatectomized mice (n = 3/group). Significantly lower levels of FIX, which were transiently expressed, have been reported [22] using naked DNA containing an expression cassette with FIX cDNA driven by the AAT promoter with the ApoE and HCR cis-acting elements. From our previous work in the context of a lentiviral vector [19] , the AAT promoter seems to be ~ 700% weaker compared with the EF1␣ enhancer/promoter as determined by measuring FIX in lentiviral-treated mice. Because the EF1␣ promoter, but not the AAT promoter, is ubiquitous and the lentiviral vector will transduce many cell types in the liver and spleen [4] , it is likely a proportion of the serum FIX was derived from nonhepatocytes. It is important to note that cis-acting elements, specifically MARs from Ig, elevated the serum levels of FIX to therapeutic levels. The levels of FIX were substantially lower than that found in adenoassociated viral (AAV) vectors [25, 26] , which used a human FIX "minigene" construct that contains intronic sequences found to enhance gene expression in vivo [22] . Future studies may be performed which will include the "minigene" in lentiviral vectors along with other cis-acting elements that may optimize transgene expression in vivo.
This study demonstrated that the cppt could reduce the need for cell cycle progression for lentiviral vectors to transduce quiescent hepatocytes in vivo. Additional lentivector manipulation will potentially allow for the production of viral vectors, which will further reduce the need for cell cycle progression in order for efficient transduction to occur in quiescent hepatocytes. In all, our study demonstrated that modifications in the lentiviral transfer vector through the addition of cis-acting elements enhanced the viral titer and transgene expression in vitro and in vivo.
METHODS
SIN vector (3Ј LTR deletion).
The KpnI/NheI fragment from pHRЈCMVlacZ [5] was cloned into pBSII-SK(-) digested with KpnI and SpeI to make pBSLTR(KpnI/NheI), which was subsequently digested with PvuII. The DNA fragment was isolated and self-ligated to make pBSLTR(KpnI/NheI-PvuII). Then pBSLTR(KpnI/NheI) was digested with PvuII and NdeI and ligated with a DNA fragment from pBSLTR(KpnI/NheI-PvuII), which was digested with EcoRV and NdeI. This plasmid, designated pBSLTR(KpnI/NheI)SIN, was digested with StuI and an annealed oligo linker with a novel NheI site was inserted generating pBSLTR(KpnI/NheI)SINlink. PCR amplification of the 3Ј LTR was carried out using the following oligos: 5Ј-TAGCTAGCT-GCTAGAGATTTTCCACACTGA-3Ј and 5Ј-CCTGGGAGCTCTCTGGCTAA-3Ј. The gel-isolated PCR product was digested with SacI and NheI and inserted into pBSLTR(KpnI/NheI-PvuII)SINlink resulting in the final clone, pBSLTRSIN.
To create the SIN vector backbone, pHR2mPGKNLSLacZ was altered such that the PGKNLSLacZ expression cassette was removed and replaced by a multicloning site. This plasmid, pHR2multiclone, was subsequently digested with KpnI, and NheI allowed for the ligation with the KpnI/NheI fragment from pBSLTRSIN, resulting in the making of pHR2PacI/PmeIlinkerSIN. This construct has removed the remaining 1456 bp of human sequence from the original cloning of the HXB2 proviral genome downstream of the 3Ј SIN LTR.
SIN vector with WPRE insertion.
Initial steps were carried out to remove the RRE. The XhoI/NotI fragment from pHR2mPGKNLSLacZ was isolated and cloned into pBS.SKII(-), making pBS(XhoI/NotI). This plasmid was subsequently digested with EcoNI and HindIII, which removed 509 bp of the envelope sequence including the 253 bp of the RRE, and then blunted with T4 DNA polymerase. The blunted linear fragment was isolated and either self-ligated resulting in pBS(XhoI/NotI-EcoNI/HindIII) or ligated with blunted BamHI/BglII RRE fragment to generate pBS(XhoI/NotIEcoNI/HindIII)RRE253. The I/NotI fragment was inserted into the pHR2PacI/PmeIlinkerSIN resulting in a plasmid, which was devoid of the RRE and known as pHR2PacI/PmeIlinkerSINRRE(-). Subsequently, the WPRE sequence was cloned from WPRE-BSKII (provided by Thomas J. Hope, Salk Institute, La Jolla, CA) as a BamHI/KpnI fragment into pHR2PacI/PmeIlinkerSINRRE(-).
Central polypurine tract. PCR amplification of the 118 bp from pCMV{D}R8.74, which is found in pol, was performed using primers as described [7] with a slight modification at the ends of each primer to incorporate unique restriction sites to facilitate cloning into different transfer plasmids. An example of a primer set used with the addition of restriction site is as follows: 5Ј-GATGGATCCTTTTAAAAGAAAAGGGGGGAT-3Ј (sense) and 5Ј-CGAAGATCTAAAATTTTGAATTTTTGTAAT-3Ј (antisense). PCR amplification was performed as follows: 94°C for 3 min, then 30 cycles of 94°C for 30 s, 60°C for 30 s and 72°C for 7 s, followed by an extension at 72°C for 7 min.
Human AAT promoter with ApoE/hepatocyte control locus (HCR) enhancer. pBS-ApoE-HCR-hAAT-FIXmg-bpA as described [22] was digested with SpeI and SalI (1.1 kb) and inserted into the pHR2EF␣ linker [19] creating pHRhAAT(A/H). pHR2hAAT(A/H)hFIX was made by inserting the FIX cDNA (BamHI/BamHI fragment) from pHR2EF1␣ hFIX [19] . The cppt was PCR amplified and inserted into the XhoI and SpeI site of the pHR2hAAT(A/H)hFIX to make pHR2chAAT(A/H)hFIX. The XhoI/BglII fragment from pHR2hAAT(A/H)hFIX and pHR2chAAT(A/H)hFIX was inserted into pHR2PacI/PmeIlinkerSINRRE(-) to create pHR(-)hAAT(A/H)hFIXR(-)W(+) and pHR(-)hAAT(A/H)hFIXR(-)W(+). The RRE (253 bp) was PCR amplified and inserted into a novel SmaI site 5Ј to the WPRE sequence to generate pHR (-) 
hAAT(A/H)hFIXR(+)W(+) and pHR(-)chAAT(A/H)hFIXR(+)W(+).
AAT cDNA expression cassette construction. pHR(-)hAAT(A/H)hFIXR(+)W(+) was digested with XhoI and NotI allowing for ligation with a XhoI/NotI fragment from pBS(XhoI/NotI-EcoNI/HindIII)RRE253. This construct was then digested with EcoRI and the AAT cDNA (EcoRI/EcoRI fragment was inserted to make pHR(+)hAAT(A/H)hAATR(-)W(+)). The Ig MAR was inserted into the XhoI site to create pHR(+)hAAT(A/H)hAATR(-)W(+)Ig(as).
Cytoplasmic LacZ expression cassette construction. The CMV promoter (blunted ClaI/blunted BamHI) was isolated from pHRЈCMVLacZ and inserted into the blunted SpeI site of pHR2chAATNLSLacZ to make pHR2cCMVNLSLacZ. The NdeI/NdeI fragment from pHRЈCMVLacZ was inserted into the NdeI/NdeI site of pHR2cCMVNLSLacZ to create pHR2cCMVsolLacZ.
PHRЈCMVlacZ was digested with KpnI and NheI and the KpnI/NheI fragment from pBSLTRSIN was ligated to make pHRЈCMVlacZSIN-18F. This plasmid was subsequently digested with NotI and XhoI and the NotI/XhoI fragment from pBS(XhoI/NotI-EcoNI/HindIII) was inserted to make pHR(-)CMVlacZSIN-18F. The WPRE fragment (EcoRI/KpnI) was inserted to make pHR(-)CMVlacZSIN-18W(+)F. The final step was the inclusion of the RRE (253 bp; EcoRI/EcoRI) to make pHR(-)CMVsolLacZR(+)W(+) and pHRЈCMVlacZR(+)W(+). The XhoI/NdIeI fragment from pHR2cCMVsolLacZ was inserted into pHR(-)CMVsollacZR(+)W(+) to create pHR(-)cCMVsollacZR(+)W(+).
Ig MAR. The Ig MAR (415 bp) was PCR amplified from mouse genomic DNA. This region of DNA, spanning 3361-3774 bp of the Ig gene as described [27] , was cloned into the SrfI site of pPCR using the PCR-Script Amp Cloning kit, and was subsequently cloned into pBS-SKII(-). Ig MAR (XhoI/XhoI fragment) was inserted 5Ј to the cppt in pHR(-)chAAT(A/H)hFIXR(+)W(+) to create pHR(-)chAAT(A/H) hFIXR(+)W(+)Ig(s) and pHR(-)chAAT(A/H)hFIXR(+)W(+)Ig(as).
Chicken lysozyme gene MAR. The 5Ј MAR from the chicken lysozyme gene (2.77 kb; XbaI/XbaI fragment) was cloned from pBS-2x(B-1-X1), which was provided by Wolf H. Stratling (Hamburg, Germany), into a novel XbaI site flanked by XhoI sites in pBS-SKII(-). pBS.ChickenMAR was digested with XhoI and the MAR fragment was cloned into the XhoI site of pHR(-)]hAAT(A/H)hFIXR(+)W(+), and both orientations of the chicken MAR were isolated (pHR(-)hAAT(A/H)hFIXR(+)W(+)ChMAR).
